Drug Profile
Trastuzumab biosimilar - Nanogen Biopharmaceutical
Alternative Names: FACEPTOR; NNG-TMABLatest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator Nanogen Biopharmaceutical Co
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Breast cancer
- Discontinued Gastric cancer
Most Recent Events
- 25 Mar 2021 Discontinued for Gastric cancer in Vietnam (IV) (Nanogen Biopharmaceutical pipeline, March 2021)
- 25 Mar 2021 Clinical development is ongoing in Breast cancer in Vietnam (IV) (Nanogen Biopharmaceutical pipeline, March 2021)
- 25 Mar 2021 Clinical trials in Breast cancer in Vietnam (IV) (Nanogen Biopharmaceutical pipeline, March 2021)